Related Experiment Videos
Five-year survival in resected T3/N2 lung cancer
1U.Z. Pellenberg, K.U. Leuven.
Acta Chirurgica Belgica
|May 1, 1989
Abstract:
The number of operated T3 lung cancers increases constantly. The absolute 5-year survival was 16.6% (9/54) and was only 9.5% (4/42) in resected N2 tumors.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Iatrogenic Atrail Septal Defect After Mitral Valve Replacement.
Acta clinica Belgica·2016
Surgical options for complete resectable lung cancer invading the phrenic nerve.
Acta chirurgica Belgica·2004
Sleeve lobectomy for non-small cell lung cancer.
Acta chirurgica Belgica·2004
Pulmonary sequestration: a comparison between pediatric and adult patients.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2001
Incentive spirometry does not enhance recovery after thoracic surgery.
Critical care medicine·2001
A novel closed book parenchyma sparing technique for giant pulmonary hydatid cysts.
Acta chirurgica Belgica·2026
Incidence of tissue-based inguinal hernia repair in Belgium: a web-based national survey.
Acta chirurgica Belgica·2026
A Multimodal Graph Neural Network Based on MRI Radi-omics for Prognostic Prediction in Locally Advanced Cervical Squamous Cell Carcinoma.
Cancer control : journal of the Moffitt Cancer Center·2026
Outcomes That Matter in Gastrointestinal Cancer Care: A Focus Group Study of Patient-Centred Outcomes Identified by Patients and Care Partners.
Health expectations : an international journal of public participation in health care and health policy·2026
Nicotinamide Metabolism Constrains Memory CD8+ T Cell Formation Through a Putative HS1BP3-SIRT1-FOXO3-BCL6 Axis.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study.
Inflammatory bowel diseases·2026
Modulating immune toxicity in ulcerative colitis using a small molecule RAB27A inhibitor.
Inflammatory bowel diseases·2026